Answer to Question 1
1, 2, 3
Rationale 1: The client should inform a healthcare provider if systolic blood pressure is less than 90 mmHg, and should not take the next dose of CCB until instructed to do so.
Rationale 2: The client should inform a healthcare provider if systolic blood pressure is less than 90 mmHg, and should not take the next dose of CCB until instructed to do so.
Rationale 3: The client should inform a healthcare provider if systolic blood pressure is less than 90 mmHg, and should not take the next dose of CCB until instructed to do so.
Rationale 4: Blood glucose increases as a side effect of beta blockers in clients with diabetes.
Rationale 5: Blood glucose increases, not decreases, as a side effect of beta blockers in clients with diabetes.
Global Rationale: The client should inform a healthcare provider if systolic blood pressure is less than 90 mmHg, and should not take the next dose of CCB until instructed to do so. The client should notify a healthcare provider if they have a very slow heart rate (less than 60 beats per minute), dizziness when standing up quickly, headache, or constipation is experienced. Blood glucose increases as a side effect of beta blockers in clients with diabetes. Nausea and vomiting are not side effects of CCB.
Answer to Question 2
2
Rationale 1: The half-life is 10 seconds.
Rationale 2: Adenosine (Adenocard, Adenoscan) is given as a 1-to2-second bolus IV injection to terminate serious atrial tachycardia by slowing conduction through the AV node and decreasing automaticity of the SA node. Its primary indication is a specific dysrhythmia known as paroxysmal supraventricular tachycardia (PSVT), for which it is a drug of choice. Because of its 10-second half-life, adverse effects are generally self-limiting.
Rationale 3: The half-life is 10 seconds.
Rationale 4: The half-life is 10 seconds.
Global Rationale: Adenosine (Adenocard, Adenoscan) is given as a 1-to2-second bolus IV injection to terminate serious atrial tachycardia by slowing conduction through the AV node and decreasing automaticity of the SA node. Its primary indication is a specific dysrhythmia known as paroxysmal supraventricular tachycardia (PSVT), for which it is a drug of choice. Because of its 10-second half-life, adverse effects are generally self-limiting.